Advertisement

Single-Stranded DNA Aptamers Against TNF and Their Potential Applications

  • Shao Tao
  • Pingfang Song
  • Xiaowei Zhang
  • Lingshu Zhang
  • Cong-Qiu ChuEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2108)

Abstract

Aptamers are short, single-stranded RNA or DNA sequences, which can bind to protein ligands with high affinity and specificity. Applications of aptamers are broad, ranging from drugs and drug delivery vehicles to biosensors. Tumor necrosis factor (TNF) is an inflammatory cytokine that plays a critical role in the pathogenesis of several autoimmune inflammatory diseases. Blocking TNF activity by monoclonal antibodies or TNF receptor fusion protein has been tremendously successful in treating these diseases. However, manufacturing these biological TNF inhibitors is expensive and a significant proportion of patients do not respond to TNF blockade. Here we describe selection of single-stranded DNA aptamers for TNF blockage, and their bioactivity in blocking TNF-mediated cytotoxicity in vitro. These TNF-binding aptamers have the potential to serve as alternatives to biological TNF inhibitors and to be used as in vivo probes for TNF detection.

Key words

Aptamers ssDNA SELEX Tumor necrosis factor In vivo imaging Therapeutics 

Notes

Acknowledgement

This work was supported by an Innovative Grant and a Pilot Grant of Rheumatology Research Foundation (CQC). ST was supported by a Graduate Student Proctorship of Rheumatology Research Foundation. LSZ was supported by a scholarship of China Scholarship Council.

References

  1. 1.
    Feldmann M, Maini RN (2010) Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 185(2):791–794CrossRefGoogle Scholar
  2. 2.
    Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5(10):578–582CrossRefGoogle Scholar
  3. 3.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ (2013) Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 19(8):621–630PubMedGoogle Scholar
  4. 4.
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681CrossRefGoogle Scholar
  5. 5.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552–1563CrossRefGoogle Scholar
  6. 6.
    Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR et al (2013) Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 72(8):1375–1381CrossRefGoogle Scholar
  7. 7.
    Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34(9):1125–1132CrossRefGoogle Scholar
  8. 8.
    Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34(12):1705–1709CrossRefGoogle Scholar
  9. 9.
    Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A (2010) Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 37(2):386–398CrossRefGoogle Scholar
  10. 10.
    Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y et al (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 20(3):313–318CrossRefGoogle Scholar
  11. 11.
    Bouchard PR, Hutabarat RM, Thompson KM (2010) Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50:237–257CrossRefGoogle Scholar
  12. 12.
    Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9(7):537–550CrossRefGoogle Scholar
  13. 13.
    Campa C, Harding SP (2011) Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12(2):173–181CrossRefGoogle Scholar
  14. 14.
    Wang AZ, Farokhzad OC (2014) Current progress of aptamer-based molecular imaging. J Nucl Med 55(3):353–356CrossRefGoogle Scholar
  15. 15.
    Marimuthu C, Tang TH, Tominaga J, Tan SC, Gopinath SC (2012) Single-stranded DNA (ssDNA) production in DNA aptamer generation. Analyst 137(6):1307–1315CrossRefGoogle Scholar
  16. 16.
    Galloway CJ, Madanat MS, Mitra G (1991) Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity. J Immunol Methods 140(1):37–43CrossRefGoogle Scholar
  17. 17.
    Shiau MY, Chiou HL, Lee YL, Kuo TM, Chang YH (2001) Establishment of a consistent L929 bioassay system for TNF-alpha quantitation to evaluate the effect of lipopolysaccharide, phytomitogens and cytodifferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells. Mediat Inflamm 10(4):199–208CrossRefGoogle Scholar
  18. 18.
    Orava EW, Jarvik N, Shek YL, Sidhu SS, Gariepy J (2013) A short DNA aptamer that recognizes TNFalpha and blocks its activity in vitro. ACS Chem Biol 8(1):170–178CrossRefGoogle Scholar
  19. 19.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N (2018) Molecular mechanisms of action of anti-TNF-alpha agents—comparison among therapeutic TNF-alpha antagonists. Cytokine 101:56–63CrossRefGoogle Scholar
  20. 20.
    Yomogida K, Wu S, Baravati B, Avendano C, Caldwell T, Maniaci B et al (2013) Cell penetrating recombinant Foxp3 protein enhances Treg function and ameliorates arthritis. Biochem Biophys Res Commun 434(2):263–267CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Shao Tao
    • 1
    • 2
    • 3
  • Pingfang Song
    • 1
    • 2
  • Xiaowei Zhang
    • 1
    • 2
  • Lingshu Zhang
    • 1
    • 2
    • 4
  • Cong-Qiu Chu
    • 1
    • 2
    Email author
  1. 1.Division of Arthritis and Rheumatic DiseasesOregon Health & Science UniversityPortlandUSA
  2. 2.Rheumatology SectionVA Portland Health Care SystemPortlandUSA
  3. 3.Division of Experimental Medicine, Faculty of MedicineMcGill UniversityMontrealCanada
  4. 4.Department of Rheumatology and Immunology, West China HospitalSichuan UniversityChengduChina

Personalised recommendations